MaxCyte ATx
전기충격 방법을 사용하여 세포 내부로 DNA, mRNA, 화합물 등을 고용량, 고효율로 전달 할 수 있는 제품
- Small scale에서 Medium scale 까지 transfection이 가능한 모델
- 7.5×10⁴ ~ 7×10⁸ cell 까지 적용 가능
- In vitro study나 연구 초기단계에서 optimization 용으로 적합
Any Cell: 80여개의 Cell type-specific protocol 내장
| Immortalized Mammalian Cells | Hematopoietic Cells | Primary Cells | |
|
|
|
|
| Mammalian Cancer Cell Lines | Stem Cells | Insect cells | |
|
|
|
|
Any Molecule: 다양한 물질의 고용량 Transfection 가능
Any Scale: 최소 75K 부터 최대 2E10 개의 세포까지 scale-up 가능 (Seamless Scalability)
다양한 세포에서 95% 이상의 Transfection Efficiency와 90% 이상의 Viability를 보임
| Item | Specification |
| ATx Instrument Dimensions | 8” wide x 19.5” high x 17” deep |
| ATx Instrument Weight | 48 lbs |
| ATx Input Power | 100-240VAC, 50-60Hz, 1.25A |
| Fuse Requirements | 2X 4A Slow Blow, 250V, 5X20mm |
| Operating Humidity | 93% max |
| Operating Temperature | 15°C – 25°C |
| Storage Temperature | 0°C – 45°C |
| Modes of Operation | Static |
| Process Volumes | 15 μL – 3.5 mL |
| Ports Available | 1 USB / 1 Ethernet |
EP volume, Cell number 에 따라서 다양한 PA 선택 가능
7.5×10⁴ ~ 7×10⁸ 개의 세포에 수초 내로 transfection이 가능하며, reaction volume은 15ul ~ 3ml 까지 가능
Processing Assembly Supporting Products
Case Study
- A Kagita et al. (2021). Efficient ssODN-Mediated Targeting by Avoiding Cellular Inhibitory RNAs through Precomplexed CRISPR-Cas9/sgRNA Ribonucleoprotein. Stem Cell Reports 16(4):985-996. doi: 10.1016/j.stemcr.2021.02.013. [자세히 보기]
- M Sasaki-Honda et al. (2020) Generation of a transgene-free iPSC line and genetically modified line from a facioscapulohumeral muscular dystrophy type 2 (FSHD2) patient with SMCHD1 p.Lys607Ter mutation. Stem Cell Res 47:101884. doi: 10.1016/j.scr.2020.101884 [자세히 보기]
References
1. COVID-19 치료제 개발 관련 연구
- S Tanaka et al. (2021). A recombinant ‘ACE2 Triple Decoy’ that traps and neutralizes SARS-CoV-2 shows enhanced affinity for highly transmissible SARS-CoV-2 variants. doi: https://doi.org/10.1101/2021.03.09.434641 [자세히 보기]
2. CRISPR/Cas9 delivery system
- [NK cells] ER Levy et al. (2021). RNA-Seq Analysis Reveals CCR5 as a Key Target for CRISPR Gene Editing to Regulate In Vivo NK Cell Trafficking. Cancers (Basel) 13(4):872. doi: 10.3390/cancers13040872. [자세히 보기]
- [CHO cells] NK Hamaker et al. (2021). A Site-specific Integration Reporter System That Enables Rapid Evaluation of CRISPR/Cas9-mediated Genome Editing Strategies in CHO Cells. Biotechnol J 15(8):e2000057. doi: 10.1002/biot.202000057 [자세히 보기]
3. Plasmid DNA electroporation into various cell lines
- [CHO cells] V Muralidharan-Chari et al. (2021) PTSelect™: A post-transcriptional technology that enables rapid establishment of stable CHO cell lines and surveillance of clonal variation. J Biotechnol 325:360-371. doi: 10.1016/j.jbiotec.2020.09.025. [자세히 보기]
- [HEK293 cells] H Kubo et al. (2021). Development of non-viral, ligand-dependent, EPHB4-specific chimeric antigen receptor T cells for treatment of rhabdomyosarcoma. Mol Ther Oncolytics 20:646-658. doi: 10.1016/j.omto.2021.03.001. [자세히 보기]
- [MEF cells] MA Carpio et al. (2021). BOK controls apoptosis by Ca 2+ transfer through ER-mitochondrial contact sites. Cell Rep 34(10):108827. doi: 10.1016/j.celrep.2021.108827 [자세히 보기]
- [T cells] K Nakamura et al. (2021). Autologous antigen-presenting cells efficiently expand piggyBac transposon CAR-T cells with predominant memory phenotype. https://doi.org/10.1016/j.omtm.2021.03.011 [자세히 보기]
4. Protein and mRNA electroporation into CD4+ T cells
- M Kolev et al. (2020). Enabling rapid and sensitive GPCR assay development with the MaxCyte ® STX™ Scalable Transfection System and the Codex ACTOne biosensor technology. Immunity 52(3):513-527.e8. doi: 10.1016/j.immuni.2020.02.006 [자세히 보기]
Webinar
